IUB SEAD RED (Revolutionary Endometrial Ablation Device Study)

One of the AUB symptoms, heavy menstrual bleeding (HMB), can lead to iron deficiency and iron deficiency anemia and in acute and severe cases, can necessitate emergency medical care. This study's focus is on the symptom of HMB which has a number of benign causes.The investigative device, the IUB SEAD™, is a novel spherical endometrial ablation device developed to allow for simple, office-based chemical EA to treat benign causes of the symptom of HMB. The suggested procedure is expected to be simpler than the currently available EA methods and yet should still reduce the need for a hysterectomy.

Inclusion Criteria:Female subject age 40 to 50 years, inclusiveSuffering from the symptom of heavy menstrual bleeding (HMB) from benign causes with no definable organic cause and are candidates for endometrial ablation or surgical treatment.PBAC score of >150 - an average of 2 consecutive screening scores prior to study treatmentAre thought to be ovulatory with cyclic predictable onset of menses with a cycle length of 24-38 days.Have either a normal appearing endometrial cavity as assessed by hysteroscopy performed within 90 days of study treatment, or one that is distorted by a FIGO Type 2 submucous leiomyoma ≤3 cm in mean diameter.Have endometrial sampling with normal histology within 6 months of the study procedure.Premenopausal status confirmed by FSH level measurement at screening (FSH < 40 IU/L). FSH level measurement will be repeated in case of a borderline resultScreening hemoglobin levels >9.0 g/dLUterine sound measurement of 6.5-12 cm (external os to internal fundus)Negative serum pregnancy test at the Screening visit and on the day of SEAD™ treatmentwomen whose sexual activity places them at risk for pregnancy must agree to use an effective, non-hormonal, non-intrauterine method of contraception throughout the course of the study. For this study, acceptable effective methods of contraception are considered to be those listed below:Barrier method, i.e., (a) condom (male or female) with spermicide or (b) diaphragm with spermicide orVasectomy (partner), orAbstinence, if in line with the preferred and usual lifestyle of the subject [where abstinence is defined as refraining from heterosexual intercourse]Subject is able to understand and sign a written informed consent formSubject is willing and able to comply with scheduled visits, treatment plan, laboratory tests, and other study proceduresThe subject demonstrates an understanding of how to record menstrual blood loss using a menstrual pictogramExclusion Criteria:Pregnant women or those who desire to conceive at any time in the futureAn endometrial cavity with any of the following: congenital malformation of (eg septate uterus), endometrial polyp >8 mm in largest dimension, FIGO Type 0 or 1 leiomyomas of any diameter or Type 2 leiomyomas > 3 cm in mean diameter; intrauterine adhesions/ synechiae that distort the endometrial cavity sufficient to impair deployment of the SEAD device.Underwent prior uterine surgery that interrupts the integrity of the uterine wall (e.g., transmural abdominal (laparoscopic or laparotomic) or hysteroscopic myomectomy and/or metroplasty during last 3 months prior to screening, classical Cesarean section, or endometrial ablationHave an abnormal endometrial biopsy that suggests either anovulation or a risk for the development of endometrial cancer (i.e., benign hyperplasia, endometrial hyperplasia with atypia, endometrial intraepithelial neoplasia, endometrial cancer)Have a documented clinical history of titanium allergy or hypersensitivity to any component of IUB™SEAD™.Suffers from active endometritis, active pelvic inflammatory disease (PID) or active sexually transmitted disease (STD)Suffers from active infection of the genitals, vagina, cervix, or uterusPresence of bacteremia, sepsis, or other active systemic infectionKnown/suspected abdominal, pelvic, or gynecological malignancy within the past 5 yearsKnown clotting defects or bleeding disordersCurrently using anticoagulant treatmentSubjects with abnormal Papanicolaou (Pap) test or atypical squamous cells of undetermined significance (ASCUS) with positive high-risk human papilloma virus (HPV) test result within the appropriate screen timeframe, and prior to SEAD™ treatment. Alternatively, a colposcopy performed prior to SEAD™ treatment, that showed evidence of dysplasia requiring treatment. In case treatment was performed > 6 months prior to enrollment and follow-up was done with no evidence of disease by clinical evaluation, the subject is eligible.Suffers from clinically significant adenomyosis indicated by subject complaints or imagingPresence of an implantable contraceptive device, unless subject agrees to have the device removed immediately on screening, and prior to PBLAC assessmentPost-partum ≤ 6-monthsCurrently participating in or considering participation in a research study of an investigational drug or device that would begin during the course of this investigational studyAny general health or mental, or other situation or condition which, in the opinion of the Investigator, could present an increased risk for the subject or impact the subject's ability to comply with protocol requirements.Has a polyp that was not removed before day of treatment